These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33629256)

  • 21. A method to determine pharmacokinetic parameters based on andante constant-rate intravenous infusion.
    Yu RH; Cao YX
    Sci Rep; 2017 Oct; 7(1):13279. PubMed ID: 29038495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
    Periclou AP; Avramis VI
    Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using three-, four-, and n-compartment closed models to estimate glomerular filtration rate during and after a constant rate intravenous infusion.
    Wu G
    Eur J Pharm Biopharm; 1998 Nov; 46(3):397-402. PubMed ID: 9885313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shortcut formulae for pharmacokinetic dosage adjustments.
    Belloto RJ
    Clin Pharmacokinet; 2009; 48(9):555-60. PubMed ID: 19725590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonstandard finite difference approach for solving 3-compartment pharmacokinetic models.
    Egbelowo OF
    Int J Numer Method Biomed Eng; 2018 Sep; 34(9):e3114. PubMed ID: 29883060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Mathematical Treatment of Multiple Intermittent Intravenous Infusions in a One-Compartment Model.
    Savva M
    Comput Methods Programs Biomed; 2021 Jun; 205():106103. PubMed ID: 33915509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.
    Landersdorfer CB; Bulitta JB; Kirkpatrick CM; Kinzig M; Holzgrabe U; Drusano GL; Stephan U; Sörgel F
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5715-23. PubMed ID: 22908169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of eltanolone following bolus injection and constant rate infusion.
    Parivar K; Wessén A; Widman M; Nilsson A
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):535-49. PubMed ID: 9300349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mean residence time concepts for pharmacokinetic systems with nonlinear drug elimination described by the Michaelis-Menten equation.
    Cheng HY; Jusko WJ
    Pharm Res; 1988 Mar; 5(3):156-64. PubMed ID: 3244627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The time to reach steady state after the administration of intravenous bolus, constant infusion, and oral immediate-release and sustained-release preparations.
    Chow MS; Sun H
    Pharmacotherapy; 1990; 10(6):400-5. PubMed ID: 2287561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonlinear pharmacokinetics of ethanol elimination in long sleep and short sleep mice.
    Gilliam DM; Bloedow DC; Collins AC
    Alcohol Clin Exp Res; 1983; 7(1):95-9. PubMed ID: 6342455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration.
    Haug KG; Weber B; Hochhaus G; Butterweck V
    Eur J Pharm Sci; 2012 Jan; 45(1-2):79-89. PubMed ID: 22085634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the two-compartment open model with Michaelis-Menten elimination kinetics to valproic acid in the bile-exteriorized rat.
    Lawyer CH; Gerber N; Lynn RK; Dickinson RG
    Res Commun Chem Pathol Pharmacol; 1980 Mar; 27(3):469-84. PubMed ID: 6770426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.
    Veng-Pedersen P; Freise KJ; Schmidt RL; Widness JA
    J Pharm Pharmacol; 2008 Oct; 60(10):1321-34. PubMed ID: 18812025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of exenatide.
    Cirincione B; Mager DE
    Br J Clin Pharmacol; 2017 Mar; 83(3):517-526. PubMed ID: 27650681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice.
    Wyska E; Szymura-Oleksiak J; Pekala E; Obruśnik A
    J Pharm Pharmacol; 2007 Apr; 59(4):495-501. PubMed ID: 17430632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of mean residence-time concepts to pharmacokinetic systems with noninstantaneous input and nonlinear elimination.
    Cheng HY; Jusko WJ
    Pharm Res; 1989 Jan; 6(1):4-12. PubMed ID: 2717515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.